Stephanie Nolan
Payments from drug & device makers
Across 233 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$458
- GSK$423
- Takeda Pharmaceuticals U.S.A., Inc.$343
- Lilly USA, LLC$335
- AstraZeneca$319
- Astellas Pharma US Inc$285
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,421100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $458 |
| GSK | 25 | $423 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $343 |
| Lilly USA, LLC | 20 | $335 |
| AstraZeneca | 18 | $319 |
| Astellas Pharma US Inc | 13 | $285 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $273 |
| Abbott | 9 | $243 |
| Bayer | 10 | $218 |
| Otsuka America Pharmaceutical, Inc. | 10 | $203 |
| Novo Nordisk | 12 | $203 |
| Axsome Therapeutics, Inc. | 7 | $165 |
| Vanda Pharmaceuticals Inc. | 10 | $144 |
| Novartis | 6 | $140 |
| Lundbeck LLC | 6 | $128 |
| Ardelyx, Inc. | 4 | $93 |
| Amgen | 5 | $89 |
| Xeris Pharmaceuticals, Inc. | 4 | $85 |
| Pfizer | 3 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Edwards Lifesciences | 1 | $34 |
| Boehringer Ingelheim | 2 | $30 |
| Philips North America LLC | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $25 |
| Viatris Specialty LLC | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$122
How this compares
$4,425 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 257 | $311,137 |
| OzempicSemaglutide | 275 | $281,411 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $85,062 |
| JanuviaSitagliptin Phosphate | 73 | $78,767 |
| EliquisApixaban | 74 | $55,392 |
| FarxigaDapagliflozin Propanediol | 77 | $55,118 |
| RybelsusSemaglutide | 15 | $37,160 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $37,106 |
| LinzessLinaclotide | 48 | $31,247 |
| JardianceEmpagliflozin | 34 | $30,827 |
| MyrbetriqMirabegron | 32 | $22,149 |
| RexultiBrexpiprazole | 13 | $22,095 |
| KerendiaFinerenone | 16 | $16,467 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $13,997 |
| XareltoRivaroxaban | 14 | $10,709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $203 | $318,571290 claims |
| Lilly USA, LLCMounjaro | $335 | $311,137257 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $319 | $95,428151 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $423 | $90,30499 claims |
| PfizerEliquis | $68 | $55,39274 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $285 | $32,07650 claims |
| AbbVieLinzess | $458 | $31,24748 claims |
| Boehringer IngelheimJardiance | $30 | $30,82734 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $203 | $22,09513 claims |
| BayerKerendia | $218 | $16,46716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Baker
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.